TargetBeta
SLC10A2
solute carrier family 10 member 2 · also NTCP2, IBAT, ASBT, ISBT · Solute carrier family 10
2 programs in company-led studies act on SLC10A2, from 2 companies: 1 in phase 3, 1 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| maralixibatrule | Mirum Pharmaceuticals | phase 4 | 213 running | – | ChEMBL |
| linerixibatrule | GlaxoSmithKline | phase 3 | 142 running | – | ChEMBL |
Conditions their studies are in
- Liver Cirrhosis, Biliary, 2 programs
- Alagille Syndrome, 1 program
- Cholangitis, Sclerosing, 1 program
- Cholestasis, 1 program
- Cholestasis, progressive familial intrahepatic 1, 1 program
- Diabetes Mellitus, Type 2, 1 program
- Intrahepatic Cholestasis of Pregnancy, 1 program
- Pruritus, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Oct 23, 2028linerixibat · GlaxoSmithKline · phase 3 · NCT07860710
- Jan 12, 2029maralixibat · Mirum Pharmaceuticals · phase 4 · NCT07823127
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.